Assessment of metabolic fluxes in the mouse brain in vivo using (1)H-[(13)C] NMR spectroscopy at 14.1 Tesla by Xin, Lijing et al.
ORIGINAL ARTICLE
Assessment of metabolic ﬂuxes in the mouse brain in vivo using
1H-[13C] NMR spectroscopy at 14.1 Tesla
Lijing Xin1,2, Bernard Lanz1, Hongxia Lei3,4 and Rolf Gruetter1,3,5
13C magnetic resonance spectroscopy (MRS) combined with the administration of 13C labeled substrates uniquely allows to
measure metabolic ﬂuxes in vivo in the brain of humans and rats. The extension to mouse models may provide exclusive prospect
for the investigation of models of human diseases. In the present study, the short-echo-time (TE) full-sensitivity 1H-[13C] MRS
sequence combined with high magnetic ﬁeld (14.1 T) and infusion of [U-13C6] glucose was used to enhance the experimental
sensitivity in vivo in the mouse brain and the 13C turnover curves of glutamate C4, glutamine C4, glutamate+glutamine C3,
aspartate C2, lactate C3, alanine C3, γ-aminobutyric acid C2, C3 and C4 were obtained. A one-compartment model was used to ﬁt
13C turnover curves and resulted in values of metabolic ﬂuxes including the tricarboxylic acid (TCA) cycle ﬂux VTCA (1.05± 0.04 μmol/g
per minute), the exchange ﬂux between 2-oxoglutarate and glutamate Vx (0.48 ± 0.02 μmol/g per minute), the glutamate-glutamine
exchange rate Vgln (0.20 ± 0.02 μmol/g per minute), the pyruvate dilution factor Kdil (0.82 ± 0.01), and the ratio for the lactate
conversion rate and the alanine conversion rate VLac/VAla (10 ± 2). This study opens the prospect of studying transgenic mouse
models of brain pathologies.
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INTRODUCTION
In vivo 13C magnetic resonance spectroscopy (MRS) in conjunction
with the administration of 13C labeled glucose provides a unique
tool to assess cerebral metabolism noninvasively. For instance,
following the infusion of [1-13C] or [1,6-13C2] glucose,
13C MRS can
dynamically monitor the 13C label incorporation into desired
carbon positions of MR detectable metabolites, e.g., glutamate
(Glu) and glutamine (Gln). Then, cerebral metabolic ﬂuxes can be
quantitatively derived from experimentally measured 13C-label
time courses using a mathematical model.1–3
Mice have been widely used for genetic modiﬁcation to
investigate the pathology of respective human diseases. The use
of 13C MRS studies on transgenic mouse models may provide
unique insights into the pathologies of various brain diseases. For
instance, the pathogenesis of Huntington’s disease may involve
the impairment of glutamate-glutamine cycling4 assessed
uniquely by 13C MRS. In vivo 13C MRS is commonly conducted in
the human5 and rat brain.6 However, for the mouse brain, the
intrinsically low sensitivity of 13C MRS and the small brain size
render the measurement of 13C labeling into metabolites in vivo
challenging. Hence, most 13C MRS studies in mouse brain were
achieved by using brain extracts.7,8 One in vivo 13C study in mouse
brain, using direct 13C MRS by image selected in vivo spectroscopy
localization with distortionless enhancement by polarization
transfer, reported time courses of C4 and C3 of Glu and Gln.9
However, the cerebral metabolic ﬂuxes remain to be determined.
In addition, a time-resolved isotopic enrichment of plasma
glucose is typically required as an input function to derive meta-
bolic ﬂuxes from 13C labeled time courses using a given metabolic
model in a 13C labeled glucose infusion study. However, frequent
blood sampling in small animals such as mouse during 13C NMR
experiment is hardly feasible due to the small blood volume of the
mouse and rather big dead volume in the catheter from the center
of the magnet to the entrance of the magnet bore.
Relative to direct 13C MRS techniques, indirect detection of 13C
through 1H combined with [1,6-13C2] or [U-
13C6] glucose admin-
istration can improve the sensitivity and allow the direct
measurement of fractional enrichments (FEs). However, the
distinct separation of 13C labeling in Glu and Gln using indirect
detection requires sufﬁciently high spectral resolution.10 Recently,
a short-echo-time (TE) full-sensitivity 1H-[13C] NMR sequence was
proposed and validated at a high magnetic ﬁeld strength of 14.1 T,
which provides high spectral resolution and signal sensitivity.11
Therefore, the aim of the present study was to use the short-TE
full-sensitivity 1H-[13C] MRS11 combined with high magnetic ﬁeld
(i.e., 14.1 T) and infusion of [U-13C6] glucose to measure the time-
resolved 13C labeling of individual metabolites with a focus on
glutamate and glutamine, to assess metabolic ﬂuxes in vivo in the
mouse brain.
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MATERIALS AND METHODS
Animal Preparation
Male ICR-CD mice (33.4± 3.7 g, n=5, Charles River, L’Arbresle Cedex, France)
were housed in standard cages, fasted over 7 hours with free access to water
and anesthetized using isoﬂurane (1% to 2%) mixed with O2. One femoral
vein was cannulated for the infusion of [U-13C6] glucose (Sigma-Aldrich, St.
Louis, MO, USA). After giving a bolus of a 20% (w/v) 99%-enriched [U-13C6]
glucose solution at an exponentially decaying rate over 5minutes, a 67%-
enriched [U-13C6] glucose solution was infused continuously for up to
3 hours.12,13 The respiration rate was continuously monitored (SA Instru-
ments Inc., Stony Brook, NY, USA) and maintained in the range of 80 to 110
breath per minute by adjusting the amount of isoﬂurane in the O2 to sustain
mouse under physiological condition, i.e., pH=7.3 to 7.4, PaCO2=30 to
42mmHg and PaO24100mmHg (data not shown), all of which allowed
sustaining normal functional activity and normal cerebral blood ﬂow.14,15 The
mouse was placed in a holder (RAPID Biomedical GmbH, Rimpar, Germany)
and the head was stereotaxically ﬁxed. Body temperature was measured by a
rectal thermosensor and maintained at 36.0± 0.5°C with the circulation of
heated water. All animal preparation procedures were performed in
accordance with local and federal guidelines (EXPANIM, Expérience sur
animaux-SCAV, Service de la consommation et des affaires vétérinaires,
Switzerland) and were approved by the Veterinary Ofﬁce of Canton de Vaud.
In Vivo NMR Spectroscopy
Magnetic resonance spectroscopy experiments were performed in a
14.1 T magnet with a 26 cm horizontal bore (Agilent Technologies, Palo
Alto, CA, USA) using a homebuilt geometrically decoupled 1H quadrature
surface coil (13mm diameter) and a linearly polarized 13C coil (10 mm
diameter) as a transceiver. Images for voxel positioning were obtained
using a multislice fast spin-echo sequence in sagittal and coronal planes
(effective TE= 54ms, repetition time=4,000 ms, echo train length= 8,
average= 4, slice thickness = 0.6 mm, slices = 25, ﬁeld of view=
20× 20mm2, data matrix = 256× 256). 13C decoupled 1H MR spectra were
acquired using a previously proposed full signal intensity 1H-[13C] NMR
sequence ‘SPECIAL-BISEP’ (Supplementary Figure S1), 11 which was
a hybrid sequence composed of SPECIAL (SPin ECho, full Intensity
Acquired Localized spectroscopy) localization part16 and a preceding 13C
editing block based on the inversion B1-insensitive spectral editing pulse
(BISEP), including a segmented 0o BIR-4 pulse with two pulse interval
delays (τ= 1/2J) in the 1H channel and an adiabatic full passage (AFP) in the
13C channel centered at the central segment of the 0o BIR-4 pulse.17 13C
editing was achieved by turning on and off the AFP pulse in the 13C
channel on alternate scans, and then the edited spectrum (i.e., 13C AFP
off–13C AFP on) contained 13C coupled 1H resonances. Outer volume
suppression and water suppression with VAPOR (VAriable Pulse power and
Optimized Relaxation delays)18 were applied before SPECIAL-BISEP. B0
inhomogeneity was optimized using ﬁrst- and second-order shimming
with FAST(EST)MAP,19,20 resulting in water linewidth of 24 to 28 Hz for a
volume of 60 μL (5 × 4× 3mm3) containing primarily cerebral cortex and
striatum (Figure 2). Adiabatic 13C decoupling10 was applied during 145ms
acquisition time. Spectra with 13C AFP off and on were acquired with 8-
scan blocks in an interleaved mode (TE = 2.8 ms, repetition time= 4
seconds) during the whole infusion experiment.
Data Analysis
After Fourier transformation and frequency correction, every four blocks
(64 averages) of spectra were summed and quantiﬁed with LCModel
(Stephen Provencher Inc., Oakville, ON, Canada).21 Nonedited 1H spectra
acquired with 13C AFP off, which contain 1H resonances coupled to both
13C and 12C nuclei, were quantiﬁed with a standard 1H MRS basis set
containing a measured macromolecular baseline22 and simulated meta-
bolite spectra.23 Another basis set including simulated metabolite spectra
of 1H resonances coupled to N-acetyl aspartate (NAA) C6, Glu (C2, C3, and
C4), Gln (C2, C3, and C4), γ-aminobutyric acid (GABA) (C2, C3, and C4),
aspartate (Asp) (C2 and C3), glucose (C2-C6), total creatine (C2 and C3),
lactate (Lac) C3, and alanine (Ala) C3 was used to quantify 13C edited MR
spectra. All metabolites concentrations were calculated using total creatine
as an internal reference by assuming its concentration of 8 μmol/g.24
Metabolic Modeling
In the metabolic reaction chain of glucose utilization in brain tissue,
pyruvate (Pyr) is the last intermediate of the glycolysis and is not only a
precursor for oxidative metabolism in the tricarboxylic acid (TCA) cycle, but
also of lactate and alanine. Given the strong activity of lactate
dehydrogenase allowing fast exchange between pyruvate and lactate as
compared with the TCA cycle rate,25,26 the 13C turnover of LacC3 closely
follows that of PyrC3 in terms of 13C FE. On the time scale of the 13C
turnover of the amino acids labeled through the TCA cycle, the FE of LacC3
can therefore be used as an input function of the metabolic system, as a
substitute to the nonmeasurable pool of pyruvate. The LacC3 turnover
curve was thus smoothed by being ﬁtted with an exponential function
FE(t) = (a · t+b)(1− e− c · t) and used as the input function for the metabolic
model. Cerebral metabolic ﬂuxes were explored by ﬁtting a one-compart-
ment metabolic model of mitochondrial metabolism (Figure 1A)2,27 to the
measured 13C labeling time courses of metabolites (i.e., GluC4, GlnC4,
GluC3+GlnC3 (GlxC3) and AspC2). The curve ﬁtting process was under-
taken in MATLAB (Version 7.11, The MathWorks, Inc., Natick, MA, USA)
using a standard built-in ordinary differential equation solver and a
modiﬁed Levenberg-Marquardt nonlinear regression method. The ﬁtting
procedure was weighted with the square root of the inverse of the
variance of the experimental noise, to compensate for the different
precisions in the measurement of the turnover curves.
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Figure 1. (A) Scheme of the mathematical model used to describe 13C label incorporation into cerebral metabolites during 13C labeled glucose
infusion. 13C label derived from 13C labeled glucose is incorporated into C3 of pyruvate. Through pyruvate dehydrogenase 13C label enters the
tricarboxylic acid (TCA) cycle and labels C4 position of 2-oxoglutarate (OG) in the ﬁrst TCA cycle turn. Via transmitochondrial transport OG
exchanges with cytosolic glutamate (Glu) which gets labeled at position C4. In the second turn of TCA cycle, OG C3 receives the label from OG C4
and Glu C3 gets further labeled. Aspartate (Asp) gets labeled via the transmitochondrial exchange with TCA cycle intermediate oxaloacetate (OAA).
C4 and C3 positions of glutamine (Gln) accumulate labels from Glu C4 and C3 through Glu-Gln cycle. VTCA, the TCA cycle rate; Vx, exchange ﬂux
between mitochondrial TCA cycle intermediates and cytosolic glutamate; Vgln, glutamate-glutamine exchange rate; Kdil, the dilution factor of the
lactate (Lac)/pyruvate pool induced by uptake of unlabeled plasma lactate. (B) Scheme of the metabolic model for the 13C labeling of AlaC3 and
LacC3 from 13C labeled glucose. VLac, lactate conversion rate; VAla, alanine conversion rate; CMRglc, cerebral metabolic rate of glucose consumption;
Vdil, dilution ﬂux in the lactate pool induced by uptake of unlabeled plasma lactate. All subscript numbers represent
13C labeled carbon position.
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In a second step, the ratio of lactate conversion rate VLac and alanine
conversion rate VAla was obtained by ﬁtting time courses of AlaC3 and
LacC3 to a compartmental model (Figure 1B) of the chemical reactions
involving pyruvate in brain glucose metabolism. In this model, the FE of
glucose is assumed to follow a step function at a level of 67% after the
start of tracer infusion, as previously shown using this type of infusion
protocol.12,13 The cerebral metabolic rate of glucose consumption (CMRglc)
was ﬁxed to 0.5 μmol/g per minute, which is a representative value for
brain glucose metabolism in anesthetized mice, as found in this study and
in the literature.7 In the case of the considered model, with a bidirectional
ﬂux with the same pyruvate pool, the FE of Lac is expected to be very close
to the FE of Ala, since the dilution ﬂux in lactate also dilutes the labeling in
Ala through the exchange with Pyr. Note that the calculated FE of AlaC3
was slightly higher than that of LacC3, which may be ascribed to a
potential underestimation of the small Ala concentration given its overlap
with macromolecule resonances at 1.4 ppm. Therefore, the FE turnover
curve of AlaC3 at steady state was scaled with the FE of LacC3, based on
the ratio between FELacC3/FEAlaC3 at steady state found in brain extracts
in Duarte et al.13 The errors of all adjusted metabolic ﬂuxes were evaluated
by Monte–Carlo simulation.
The equations describing the mathematical modeling approaches used
in this study are reported in appendix, as Supplementary information.
RESULTS
Nonedited (Figure 2A) and edited 1H MR spectra (Figure 2B)
acquired from the volume of interest of 60 μL in the mouse brain
using SPECIAL-BISEP show good spectral quality at 14.1 T in this
study, such as high spectral resolution, e.g., the separation of
GluC4 and GlnC4, and the absence of contamination signal from
extraneous lipids, which allows the measurement of lactate and
alanine. In the 13C edited spectra, 13C labeled 1H resonances in the
mouse brain can be observed in LacC3, AlaC3, GluC4, GlnC4,
GlxC3, GlxC2(GluC2+GlnC2), AspC3, AspC2, GABAC3, GABAC2, and
Glc(C2-C6) (Figure 2B).
To show the dynamic incorporation of 13C label into individual
carbon positions of metabolites, edited spectra containing 13C-
coupled 1H resonances were summed over 5 minutes for 90
minutes after the start of [U-13C6] glucose infusion (Figure 3). Note
that 13C labeling into Glc and Lac can already be observed during
the second 5-minute acquisition after the start of infusion.
Subsequently, carbon positions of Ala, Glu, Gln and GABA were
labeled, respectively (Figure 3).
To determine the total concentration of metabolites (13C+12C)
and the concentrations of 13C labeled metabolites, nonedited and
edited 1H spectra were analyzed using LCModel. The pool sizes of
glutamate (9.1 ± 0.5 μmol/g, mean± s.e.m.), glutamine (3.4 ± 0.1
μmol/g), and aspartate (2.1 ± 0.2 μmol/g) were measured simulta-
neously from the nonedited 1H spectra. The average time courses
of 13C labeled GluC4, GlnC4, GlxC3, AspC2 and GABA(C2, C3, and
C4) concentration were obtained from the edited spectra with a
temporal resolution of 4.3 minutes during 180-minute infusion of
[U-13C6] glucose (Figure 4).
To determine the TCA cycle ﬂux (VTCA = 1.05 ± 0.04 μmol/g per
minute, mean± s.d.), the exchange ﬂux between 2-oxoglutarate
(mitochondrial TCA cycle intermediate) and glutamate (cytosolic
amino acid) (Vx = 0.48 ± 0.02 μmol/g per minute), the Glu-Gln
exchange rate (Vgln = 0.20 ± 0.02 μmol/g per minute) and the
dilution factor (Kdil = 0.82 ± 0.01), the average time courses of
GluC4, GlnC4, GlxC3, and AspC2 were ﬁtted by a one-compart-
ment model of mitochondrial metabolism using ﬁtted LacC3 time
course as the input function (Figures 4A–4C). The comparison of
metabolic ﬂuxes obtained in mouse (ex vivo), rat, and human
(in vivo) brains is summarized in Table 1.
To determine the ratio of VLac/VAla (10 ± 2), the turnover curves
of LacC3 and AlaC3 (Figure 5A) were ﬁtted, assuming a glucose
utilization CMRglc of 0.5 μmol/g per minute.
7 To investigate the
effect of the assumed CMRglc value on the assessment of VLac/VAla
ratio, VLac/VAla ratios were calculated by varying CMRglc values
(Figure 5B). For CMRglc values lower than 0.45 μmol/g per minute,
the simulated curves failed to describe the initial rising portion of
the measured LacC3 enrichment curve. This value was therefore
used as a minimum in the analysis. Error bars represents the
standard deviation determined by Monte–Carlo simulations. The
VLac/VAla ratio was found to be between 6.6 and 11.6 for the
considered CMRglc range. For an assumed value of CMRglc of
0.5 μmol/g per minute,7 the ratio was 10 ± 2. The pool size of Ala
and Lac may vary due to physiological conditions, such as the
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Figure 2. Representative coronal and sagittal fast spin-echo images of the mouse brain with the volume of interest (VOI) for magnetic
resonance spectroscopy (MRS) measurement. Averaged nonedited (A) and edited (B) 1H magnetic resonance (MR) spectra acquired in the
mouse brain during ﬁrst hour of [U-13C6] glucose infusion (VOI= 60 μL, nt= 960, no apodization was applied). Ala, alanine; Asp, aspartate;
GABA, γ-aminobutyric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; Glx, Glu+Gln; Lac, lactate; MM, macromolecules; NAA,
N-acetyl aspartate; tCr, total creatine.
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higher plasma glucose level during [U-13C6] glucose infusion.
From the 1H MRS data, we observed a net production of lactate
(0.01 μmol/g per minute) and in a smaller extent of alanine
(0.002 μmol/g per minute). When this metabolic nonsteady-state
condition was added to the metabolic model, i.e., considering
linearly increasing pool sizes, no statistically signiﬁcant difference
was found for the VLac/VAla ratio (data not shown).
DISCUSSION
The present study measures for the ﬁrst time in vivo in the mouse
brain the 13C label incorporation into brain metabolites using 1H-[13C]
MRS with the concomitant determination of the TCA cycle ﬂux VTCA,
the exchange ﬂux between 2-oxoglutarate and glutamate Vx, the
Glu-Gln exchange rate Vgln, the pyruvate dilution factor Kdil and
the ratio VLac/VAla.
1H-[13C] Magnetic Resonance Spectroscopy in the Mouse Brain
Due to the small size of the mouse brain and the intrinsic low
sensitivity of 13C MRS, several strategies were used in this study to
enhance sensitivity of the measurement. The use of [U-13C6]
glucose infusion increased the sensitivity of the measurement by
two-fold relative to [1-13C] glucose by labeling both molecules of
[3-13C] pyruvate from [U-13C6] glucose through glycolysis. In
addition, as an alternative to direct-detected 13C MRS,9 detection
of 13C labeling through coupled 1H nuclei intrinsically increased
the experimental sensitivity. The application of SPECIAL-BISEP11 at
ultra-high magnetic ﬁeld of 14.1 T further increased the quality of
in vivo spectra from the mouse brain in terms of signal-to-noise
ratio, spectral resolution, and localization performance. Moreover,
the nonedited 1H spectra allow the straightforward measurement
of metabolites pool size in vivo, which is especially practical for
recording the pool size of those metabolites that may vary during
the infusion experiment.13,28 Although the application of 1H-[13C]
MRS at 14.1 T improved the spectral dispersion of GluC4 and
GlnC4 (Figure 2B), the separation of labeling in C2 and C3 of Glu
and Gln was not complete.
Input Function for Metabolic Modeling
As a major energy source of the brain, glucose is ﬁrst transported
into brain across the blood–brain barrier and then degraded into
pyruvate by the glycolytic pathway. Pyruvate can then be trans-
ported into mitochondria and oxidized in the TCA cycle. It can also
be converted to lactate through lactate dehydrogenase, which has a
higher activity than that of the pyruvate dehydrogenase.25
Therefore, following the glucose metabolic pathway, several
candidates, e.g., plasma glucose, brain glucose, lactate, and
pyruvate could serve as an input function in the mathematic
modeling to derive metabolic ﬂuxes. However, due to small pool
size of pyruvate, it can only be detected with sensitivity
enhancement using dynamic nuclear polarization.29
To date, when using direct 13C MRS, it has been hardly feasible
to measure the time-resolved FE of metabolic pools such as
glucose or lactate in vivo. Therefore, a time-resolved FE of plasma
glucose was commonly obtained from blood sampling during the
MRS experiment and then used as an input function to derive
metabolic ﬂuxes using a given metabolic model in a 13C labeled
glucose infusion study.13,30 However, frequent blood sampling
during 13C NMR experiments remains challenging in the mouse
due to its small blood volume. Recently, one study showed the
blood sampling during 13C MR experiments in young rat (~100 g)
by using a speciﬁcally designed animal holder.31
Alternatively, the measure of FE of brain glucose using 1H-[13C]
MRS has been reported in the rat brain;10 however, this remains
challenging as it heavily relies on excellent water suppression and
shimming performance. The optimization of ﬁeld inhomogeneity
in mouse brain is highly demanding on shimming capacity
because of an increased susceptibility gradient comparing with rat
brain24 and becomes even more challenging at 14.1 T compared
with 9.4 T.32 Therefore, in the current study, the reliable measure-
ment of C1 glucose at 5.2 ppm was not applicable in mouse brain.
Other 1H resonances coupled to C2-C6 of glucose present a number
of peaks (3.3 to 3.8 ppm) overlapping with macromolecule baseline
and many metabolites. This results in the underestimation of total
glucose concentration in the nonedited spectra and overestimation
of FE of brain glucose. Therefore, brain glucose might not be best
candidate as the input function in this study.
However, the mouse brain contains higher level of lactate (3 to
5 mmol/L)24,33 across four brain regions relative to rats (1 to
2 mmol/L)34 and human (~1mmol/L),35 leading to direct time
course measurements of lactate FE using 1H-[13C] MRS (Figure 4C).
Compared with plasma or brain glucose, which is several
biochemical steps further from the TCA cycle, the lactate pool is
likely to represent closely the FE of pyruvate. In addition, lactate
can also be transported into the brain via monocarboxylate
transporters and utilized as brain fuel.36 The use of lactate as an
input function could take into account the potential 13C labeling
from the blood. Therefore, the brain lactate signal is the most
favourable and straightforward candidate for input function in the
mouse brain.
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Figure 3. Stack plot of 13C labeling incorporation into cerebral
metabolites during the ﬁrst 90 minutes of [U-13C6] glucose infusion
with time resolution of 5minutes. No baseline correction and water
signal removal were applied.
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Figure 4. Average time courses of (A) GlnC4 (□) and GluC4 (○), (B) GlxC3 (○) and AspC2 (□), (C) LacC3, and (D) GABA C2(*), C3(□), and C4(○)
during 180-minute [U-13C6] glucose infusion (n= 5). LacC3 time course was ﬁtted with an exponential function. The ﬁtting curves of GluC4,
GlnC4, GlxC3, and AspC2 were the best ﬁt obtained from one-compartment metabolic modeling. Spectra were average over 17minutes for
time courses of GABA C2, C3, and C4. Polynomial function was used to ﬁt GABA C2, C3, and C4 for visualization purpose. Asp, aspartate; Gln,
glutamine; Glu, glutamate; Lac, lactate.
Table 1. Metabolic ﬂuxes (μmol/g per minute, mean± s.d.) obtained in rat, human, and mouse brain using 13C MRS
VTCA
n VTCA Vx VNT Vg VPC Anesthetic VOI location Reference
Rata 0.44± 0.01 0.74± 0.02 0.76± 0.07b 0.12± 0.01 0.23± 0.02 0.07± 0.01 α-Chloralose Whole brain Duarte et al13
Ratc 0.37± 0.06 0.73± 0.06 0.46± 0.05b 0.15± 0.01 0.27± 0.02 0.09± 0.01 α-Chloralose Cortex Lanz et al37
Ratd − 0.71± 0.02 0.88± 0.08 − − − α-Chloralose Whole brain Henry et al12
Rata 0.79± 0.15 0.93± 0.15 9.6± 6.9 0.31± 0.07 0.04e 0.096e Halothane Gray matter de Graaf et al6
Rata 0.20± 0.11 0.31± 0.11 6.4± 3.8 0.02± 0.04 0.01e 0.096e Halothane White matter de Graaf et al6
Rata 0.42± 0.09 0.54± 0.09 6.7± 4.1 0.18± 0.12 0.02e 0.096e Halothane Subcortex de Graaf et al6
Humand − 0.80± 0.10 − − − − − Gray matter Mason et al39
Humand − 0.17± 0.01 − − − − − White matter Mason et al39
Humand − 0.73± 0.19 57± 26 0.47± 0.70 − − − Occipital-parietal Mason et al40
Humand 0.57± 0.06 0.72± 0.07 0.57± 0.19 0.17± 0.05 0.06± 0.04 0.09± 0.02 − Visual cortex Gruetter et al38
Mousef 0.91± 0.05 1.06± 0.07 99.96 0.36± 0.02 0.13± 0.04 0.02± 0.03 Halothane Cortex extract Tiwari et al7
Mousef 0.75± 0.05 0.83± 0.07 99.96 0.18± 0.01 0.02± 0.04 0.06± 0.03 Halothane Striatum extract Tiwari et al7
Mouseg − 1.05± 0.04 0.48± 0.02 0.20±0.02h − − Isoﬂurane Cortex and striatum Current study
Abbreviations: MRS, magnetic resonance spectroscopy; TCA, tricarboxylic acid; VTCA
n , rate of neuronal TCA cycle; TCA cycle ﬂux VTCA= VTCA
n +Vg+VPC; Vg, rate of
glial TCA cycle; VPC, rate of pyruvate carboxylase; VNT, apparent rate of glutamate neurotransmission; VOI, volume of interest.
a[1,6-13C2] glucose infusion.
bExchange rate between 2-oxoglutarate and glutamate in neurons. c[2-13C] acetate infusion. d[1-13C] glucose infusion. eAssumed values. fEx vivo, [1,6-13C2]
glucose and [2-13C] acetate infusion. g[U-13C6] glucose infusion.
hVNT was set to Vgln in the one-compartment model.
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Metabolic Fluxes
The value of TCA cycle ﬂux (VTCA = 1.05 ± 0.04 μmol/g per minute)
representing essentially glutamatergic neuron activity is in agree-
ment with the results obtained from mouse brain extracts
(Table 1).7 As shown in Table 1, mouse brains showed a higher
TCA cycle ﬂux compared with human and rat brain, suggesting
distinct kinetics for the mouse. The Glu-Gln exchange rate of
0.20 ± 0.02 μmol/g per minute for cerebral cortex and striatum falls
in the range of reported ex vivo values of 0.18 ± 0.01 and
0.36 ± 0.02 μmol/g per minute in striatum and cortex.7 The
transmitochondrial ﬂux Vx (0.48 ± 0.02 μmol/g per minute) sum-
marizing the exchange between 2-oxoglutarate and cytosolic
glutamate was measured for the ﬁrst time in the in vivo mouse
brain and was found on the same order of magnitude as the TCA
cycle rate, similarly to previous studies in rats13,37 and humans.38
In this study, we applied a one-compartment model analysis of
brain energy metabolism based on the turnover curves GluC4,
GlnC4, GlxC3, and AspC2. Since brain tissue is composed of many
different cell types with distinct roles in energy metabolism, it
would be desirable to develop the model into a more complex
scheme closer to the tissue biochemical complexity. A next step
would be to consider a two-compartment approach1,13,37 to
distinguish between neuronal and astrocytic metabolism in the
13C labeling of glutamate, glutamine and aspartate. However, to
characterize properly the activity of astrocytic and neuronal TCA
cycles separately, the separate acquisition of the positions C4 and
C3 of glutamate and glutamine is at least necessary,1 when
infusing [1,6-13C]glucose. The main reason is the different labeling
pattern of the position C3 induced in the astrocytic compartment
by the astrocytic-speciﬁc pyruvate carboxylase. This cell-speciﬁc
labeling pattern enables to decouple the effects of neuronal and
astrocytic TCA activity on the observed turnover curves by a glial-
speciﬁc dilution of glutamine C3. In the present study using
[U-13C]glucose and limited to the measurement of GlxC3 due to
spectral overlap, this cell-speciﬁc labeling pattern was not
observed and the use of two-compartment modeling approach
leads to strong correlations between the determined metabolic
rates in the neuronal and astrocytic compartments (data not
shown). This underdetermination can either be solved by ﬁxing
some metabolic rates using a priori knowledge or decreasing the
level of complexity of the model, i.e., reducing it to a one-
compartment approach. Future studies enabling the separate
measurement of the C3 and C2 positions of glutamate and
glutamine are expected to give a cell-speciﬁc insight in cerebral
oxidative metabolism in the mouse.
Metabolic concentrations, required for the determination of the
metabolic ﬂuxes, are commonly varying strongly with cerebral
regions as shown in the human35, rat,34 and mouse24 brains.
Therefore, it is crucial to determine the metabolic pool size in the
studied volume of interest (VOI). One of the advantages of 1H-[13C]
MRS is the simultaneous measurement of metabolic pool sizes
from nonedited spectra. The metabolite values measured in the
VOI containing mainly cerebral cortex and striatum in this study
are in the range of those reported in vivo in the mouse striatum
and cortex.24
Metabolic Flux Ratio of VLac/VAla
In the present study, we report for the ﬁrst time the in vivo
measurement of 13C label incorporation into Lac and Ala in the
mouse brain. A separate metabolic model of the biochemical
reactions involving the production of alanine and lactate from
pyruvate was therefore developed to enable the characterization
of the dynamics of the labeling of alanine and lactate (Figure 1B).
The conversion rate between pyruvate and alanine through
alanine aminotransferase was expected to be on the same order
of magnitude as the conversion between pyruvate and lactate.
Therefore, the strategy of substituting the unknown FE time
course of PyrC3 by the measured FE turnover curve of LacC3 as
used for the modeling of the TCA cycle activity was not applicable.
An alternative approach would be to work with another upstream
substrate, such as the plasma glucose FE as an input function.
With the applied glucose infusion protocol, the FE of glucose in
blood has been shown to reach steady state within 5 minutes.13
Blood glucose FE was therefore modeled as a step function.
However, the biochemical pathways and intermediates from
plasma glucose to cerebral pyruvate are numerous (i.e., glucose
transport, phosphorylation, and glycolysis). All these intermediate
labeling pools potentially delay the turnover of pyruvate as
compared with blood glucose and therefore may affect the
kinetics of 13C uptake in alanine and lactate. Since the glycolytic
process is expected to be relatively slow compared with the
conversion between pyruvate and lactate or alanine, this effect
may not be negligible. Therefore, the separate evaluation of
CMRglc and the labeling ﬂuxes VAla and VLac is not possible without
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Figure 5. (A) Average time courses of AlaC3 and LacC3 (n= 5) were shown and ﬁtted with a mathematical model to calculate VLac/VAla. (B) The
effect of the assumed cerebral metabolic rate of glucose consumption (CMRglc) value on the ratio of VLac/VAla. Ala, alanine; FE, fractional
enrichment; Lac, lactate.
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measuring the FE of PyrC3. However, since this labeling delay due
to glycolysis affects pyruvate labeling, which is the last precursor
for lactate and alanine, the dynamics of AlaC3 and PyrC3 turnover
curves carries information on the relative conversion rates VAla and
VLac, which could be determined in this study, as conﬁrmed by
Monte–Carlo simulation (VLac/VAla = 10 ± 2).
In this study, a representative CMRglc of 0.5 μmol/g per minute
7
was assumed to avoid potential mathematical underdetermina-
tion of the metabolic model. Further analysis (Figure 5B) showed
that assumed CMRglc in a range of 0.45 to 2 μmol/g per minute
resulted in a ratio VLac/VAla from 6.6 to 11.6. Note that the gradual
increase in lactate and alanine concentrations measured by 1H
MRS did not affect the determination of the ratio VLac/VAla.
We conclude that high quality 1H-[13C] NMR spectra can be
acquired from a volume as small as 60 μL in mouse brain in vivo at
14.1 T. This allows to obtain 13C labeling turnover curves of GluC4,
GlnC4, GlxC3, and for the ﬁrst time, AspC2, AlaC3, GABA (C2, C3,
and C4) as well as LacC3 that offers precursor information to
determine a number of metabolic ﬂuxes without additional blood
sampling. This study opens the prospect of studying transgenic
mouse models of brain pathologies.
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